Cytarabine Ocfosfate, a New Oral Ara-C Analogue, in the Treatment of Acute Leukemia and Myelodysplastic Syndromes

  • Ryuzo Ohno
  • YNK-01 Study Group
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 37)

Abstract

Cytarabine ocfosfate (1-β-D-arabinofuranosylcytosine-5′-stearyl-phosphate, YNK-01) is a prodrug of Ara-C, and is slowly converted to Ara-C in the liver, releasing Ara-C into the blood over a prolonged period. It is resistant to both cytidine deaminase and phosphodiesterase. Its activity does not depend on the administration schedule and route, and unlike Ara-C, single administration is as effective as daily administration. YNK-01 is the first commercially available oral derivative of Ara-C in Japan. Phase I studies by single or 5-day consecutive oral administration revealed dose-dependent plasma levels of Ara-C, and the dose-limiting toxicities were thrombocytopenia and gastrointestinal side effects. Five daily oral administrations of 100 mg of YNK-01 gave continuous plasma Ara-C levels at around 1 ng/ml on day 1, and 2 to 4 ng/ml on day 5, plasma Ara-C was detected up to day 7. A phase II study with oral daily administration of 100–450 mg resulted in 2 CR (3%) and 10 PR (18%) in 58 evaluable patients with previously-treated AML, acute leukemia from MDS, CML-BC, hypoplastic acute leukemia or ALL, and 2 CR (4%), 6 GR (13%) and 5 PR (11%) in 45 evaluable patients with RAEB, RAEB-T and CMMoL. Major toxic effects were myelosuppression and gastrointestinal toxicity, including anorexia (35%), nausea/vomiting (19%), diarrhea (9%), malaise (18%), and elevation of GOT/GPT (9%), LDH (6%) and ALP (4%).

In spite of such disadvantages as unpredictable absorption due to nausea/vomiting) this newly developed orally administrable Ara-C analogue will be useful for leukemia, to which low-dose Ara-C is indicated) such as MDS and acute leukemia in elderly patients.

Keywords

Toxicity Leukemia Anemia Oncol Diarrhea 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Champlin R, Gale PR: Acute myelogenous leukemia, Recent advance in therapy. Blood 1987; 69: 1551–1562.PubMedGoogle Scholar
  2. 2.
    Ohno R: Current progress in the treatment of adult acute leukemia in Japan. Jpn J Clin Oncol 1993; 22: 85–97.Google Scholar
  3. 3.
    Saneyoshi M, Morozumi M, Kodama K et al. Synthetic nucleosides and nucleotides. XVI. Synthesis and biological evaluations of a series of 1-β-D-arabinofuranosylcytosine 5′-alkyl or arylphosphates. Chem Pharm bull 1980; 28: 2915–2923.PubMedCrossRefGoogle Scholar
  4. 4.
    Kodama K, Morozumi M, Saitoh K et al. Antitumor activity and pharmacology of 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate: an orally active derivative of l-β-D-arabinofuranosylcytosine. Jpn J Cancer Res 1989; 80: 679–685.PubMedCrossRefGoogle Scholar
  5. 5.
    Fukuoka M, Miyazaki T, Yoshida Y et al. Phase I study of YNK-01 (1-β-D-arabinofuranosylcytosine-5′-stearylphosphate), Gan-to-Kagakuryouhou 1990; 17: 2213–2219.Google Scholar
  6. 6.
    Tatsumi N, Yamada K, Ohshima T et al. Phase II study of YNK-01 (1-β-D-arabinofuranosylcytosine 5′-stearylphosphate) on hematological malignancies, Gan-to-Kagakuryouhou 1990; 17: 2387–2395.Google Scholar
  7. 7.
    Ohno R, Tatsumi N, Hirano M et al. Treatment of myelodysplastic syndromes with orally administered 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate. Oncol 1991; 48: 451–53.CrossRefGoogle Scholar
  8. 8.
    Hori K, Tsuruo T, Naganuma K et al. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-β-D-arabinofuranosylcytosine in mice. Cancer Res 1984; 44: 172–177.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • Ryuzo Ohno
    • 1
  • YNK-01 Study Group
    • 1
  1. 1.Department of Medicine IIIHamamatsu University School of MedicineHamamatsuJapan

Personalised recommendations